RT Journal Article
SR Electronic
T1 Emergence in Southern France of a new SARS-CoV-2 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the spike protein
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.24.21268174
DO 10.1101/2021.12.24.21268174
A1 Philippe Colson
A1 Jérémy Delerce
A1 Emilie Burel
A1 Jordan Dahan
A1 Agnès Jouffret
A1 Florence Fenollar
A1 Nouara Yahi
A1 Jacques Fantini
A1 Bernard La Scola
A1 Didier Raoult
YR 2021
UL http://medrxiv.org/content/early/2021/12/29/2021.12.24.21268174.abstract
AB SARS-CoV-2 variants have become a major virological, epidemiological and clinical concern, particularly with regard to the risk of escape from vaccine-induced immunity. Here we describe the emergence of a new variant. For twelve SARS-CoV-positive patients living in the same geographical area of southeastern France, qPCR testing that screen for variant-associated mutations showed an atypical combination. The index case returned from a travel in Cameroon. The genomes were obtained by next-generation sequencing with Oxford Nanopore Technologies on GridION instruments within ≈8 h. Their analysis revealed 46 mutations and 37 deletions resulting in 30 amino acid substitutions and 12 deletions. Fourteen amino acid substitutions, including N501Y and E484K, and 9 deletions are located in the spike protein. This genotype pattern led to create a new Pangolin lineage named B.1.640.2, which is a phylogenetic sister group to the old B.1.640 lineage renamed B.1.640.1. Both lineages differ by 25 nucleotide substitutions and 33 deletions. The mutation set and phylogenetic position of the genomes obtained here indicate based on our previous definition a new variant we named “IHU”. These data are another example of the unpredictability of the emergence of SARS-CoV-2 variants, and of their introduction in a given geographical area from abroad.Competing Interest StatementDR has a conflict of interest being a consultant for Hitachi High-Technologies Corporation, Tokyo, Japan from 2018 to 2020. All other authors have no conflicts of interest to declare. Funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.Funding StatementThis work was supported by the French Government under the Investments for the Future program managed by the National Agency for Research (ANR), no. Mediterranee-Infection 10-IAHU-03 Region Provence Alpes Cote d Azur and European funding FEDER PRIMMI (Fonds Europeen de Developpement Regional-Plateformes de Recherche et d Innovation Mutualisees Mediterranee Infection), no. FEDER PA 0000320 PRIMMI Hitachi High-Technologies Corporation, Tokyo, Japan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University Hospital Institute Mediterranee Infection gave ethical approval for this work (No. 2021-029).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://www.gisaid.org. https://www.gisaid.org